If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-06. Numbers and descriptions here follow the published literature rather than marketing material.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Celiac disease Crohn's disease Ulcerative colitis Chronic pancreatitis Cystic fibrosis Intestinal infection, e.g. Clostridium difficile infection. Malabsorption Short bowel syndrome Attempts to reduce the odor of feces (and flatus) are largely based on animal research carried out with industrial applications, such as reduced environmental impact of pig farming. See also: Flatulence#Management, odor. Many dietary modifications/supplements have been researched, including:
1962 Pittsburgh Award 1963 Election to membership in the National Academy of Sciences 1963 Borden Medal 1963 Chancellors Medal, University of Pittsburgh 1972 Mellon Lecture, University of Pittsburgh 1976 Senior Scientist Award, Alexander Von Humboldt Foundation, Bonn, West Germany 1981 Third Alan E. Pierce Award by the American Peptide Chemists 1983 Japan Society for the Promotion of Sciences Fellowship Award 1987 First Huggins Memorial Award, University of Pittsburgh
Alongside his collaborators, Karl Piez and George Martin at the National Institute of Health, Gross discovered that collagen was composed of three polypeptide chains. These experiments opened up the field of collagen biology. In the early 1960s, Gross began searching for mechanisms whereby collagen fibers are degraded during tissue remodeling alongside Belgian postdoctoral fellow Charles Lapiere. Gross reasoned that collagenolytic enzymes, which previously had been identified only in bacteria, could be made only when and where they were needed. They looked for collagenase in the medium from tissue implants in culture. Together, they found the enzyme and characterized its mechanism of action and its unique cleavage site. With such colleagues as Martin Tanzer, Utaka Nagai, Andrew Kang, and others, Gross continued studies of mechanisms of collagenolysis, lathyrism, and wound healing. In 1969, Gross was promoted to Professor of Medicine at Harvard Medical School and named Biologist at the Massachusetts General Hospital. Scientists from all over the world worked in Gross's Developmental Biology Laboratory in the Department of Medicine at the Massachusetts General Hospital. Gross continued to make important observations on collagen structure, mechanisms of fibrillogenesis, the role of hyaluronic acid and hyaluronidase in wound healing, embryogenesis and limb regeneration, the origin of corneal ulcers, and control of collagenase production. Gross died at age 96 in Waban, Massachusetts of natural causes
== Medical uses == Escitalopram is approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder in adolescents and adults, and generalized anxiety disorder (GAD) in adults, in dosage from 5 to 20 mg. In European countries including the United Kingdom, it is approved for depression and anxiety disorders; these include: generalized anxiety disorder, social anxiety disorder (SAD), obsessive–compulsive disorder (OCD), and panic disorder with or without agoraphobia. In Australia it is approved for major depressive disorder.
This use a treatment for disease was pioneered in 1890 by Emil von Behring and Shibasaburo Kitasato, who first demonstrated that the endotoxin from the infectious diseases diphtheria and tetanus could be used to prevent or cure non-immunized animals using serum transfusions from an immune animal to a susceptible one. Building on in this logic, and at the same session of the Society of Biology in Paris on February 10, 1894, Albert Calmette at the Pasteur Institute and independently Césaire Phisalix and Gabriel Bertrand at the Department of Pathology and Chemistry in the National Museum of National History in France, announced that they had achieved treatment of a vulnerable animal with serum from an immunized one both using snake venom. Calmette went on subsequently to immunize horses using venom from Indian cobras, and the resulting Serum Antivenimeux (antivenomous serum) became the first commercially available antivenom product. In 1895 Sir Thomas Fraser, Professor of Medicine at the University of Edinburgh, also produced a serum to act against cobra venom. His "antivenene" was effective in the laboratory. In 1901, Vital Brazil, working at the Instituto Butantan in São Paulo, Brazil, developed the first monovalent and polyvalent antivenoms for Central and South American Crotalus and Bothrops snakes, as well as for certain species of venomous spiders, scorpions, and frogs. In Mexico in 1905, Daniel Vergara Lope developed an antivenom against scorpion venom, by immunizing dogs. In Australia, the Commonwealth Serum Laboratories (CSL) began antivenom research in the 1920s.
Sources: en.wikipedia.org
During the War of the Triple Alliance, Peru was a country that protested against the alleged attempts to conquer Paraguay by the member countries of the Triple Alliance (of which Argentina was a part together with Uruguay and Brazil). For the rest of the continent, this war was perceived as an attempt to conquer and divide Paraguay among the allies. The attempt against the independence of one of the countries of the continent was feared as a terrible precedent for potential geopolitical disorders and possible expansionist projects in the governments of the area, Argentina being very frowned upon in the eyes of Peru. The controversial Secret Treaty of the Triple Alliance was seen in Peruvian diplomacy as a violation of Paraguay's sovereignty and integrity as a country. Thus, the perception of that war was understood, in the public eye, as the arrogance of 3 allied countries that wanted to seize Paraguay's territory and even destroy its sovereignty, generating analogies with the Second French intervention in Mexico or the Spanish-South American War, that happened simultaneously during the 1860s, comparing them as a form of imperialism not different from that of the Europeans. Seen in this way, no distinction was made regarding a conquest, especially of a Latin American country, by an American government or a European government, in the eyes of society, both acts were reprehensible.
==== "Smart" hydrogel dressings ==== "Smart" hydrogels which are stimuli-responsive (i.e. thermoresponsive, bioresponsive, pH-responsive, photoresponsive, and redox-responsive) are also being produced.
Flight cases and transit cases are usually custom designed for shipping and carrying fragile equipment: audio visual, camera, instruments, etc. Although generally light in construction, they tend to have reinforced edges and corners.
The brick, five-story Folger Coffee Company Building at 101 Howard in San Francisco, California is the former headquarters of Folgers. It is listed on the United States National Register of Historic Places. The building still has a sign saying "The Folgers Coffee Company" on one corner. On August 2, 2011, the Folger Building was purchased by the University of San Francisco, marking a return to the university's roots in downtown San Francisco.
Sources: en.wikipedia.org
peptidyl(2-hydroxyglycine) + dehydroascorbate + H2O The 3 substrates of this enzyme are peptidylglycine, ascorbate, and O2, whereas its 3 products are peptidyl(2-hydroxyglycine), dehydroascorbate, and H2O. This enzyme belongs to the family of oxidoreductases, specifically those acting on paired donors, with O2 as oxidant and incorporation or reduction of oxygen. The oxygen incorporated need not be derived from O2 with reduced ascorbate as one donor, and incorporation of one atom of oxygen into the other donor. The systematic name of this enzyme class is peptidylglycine,ascorbate:oxygen oxidoreductase (2-hydroxylating). Other names in common use include 2-hydroxylase, alpha-amidating enzyme, peptide-alpha-amide synthetase, synthase, peptide alpha-amide, peptide alpha-amidating enzyme, peptide alpha-amide synthase, alpha-hydroxylase, alpha-amidating monooxygenase, PAM-A, PAM-B, and PAM. It employs one cofactor, copper.
This abuse of power by local leaders exacerbated the violent purges and terror campaigns carried out by Stalin against members of the party deemed to be traitors. With the Great Purge (1936–1938), Stalin rid himself of internal enemies in the party and rid the Soviet Union of any alleged socially dangerous and counterrevolutionary person who might have offered legitimate political opposition to Marxism–Leninism. Stalin allowed the secret police NKVD (People's Commissariat for Internal Affairs) to rise above the law and the GPU (State Political Directorate) to use political violence to eliminate any person who might be a threat, whether real, potential, or imagined. As an administrator, Stalin governed the Soviet Union by controlling the formulation of national policy, but he delegated implementation to subordinate functionaries. Such freedom of action allowed local communist functionaries much discretion to interpret the intent of orders from Moscow, but this allowed their corruption. To Stalin, the correction of such abuses of authority and economic corruption were responsibility of the NKVD. In the 1937–1938 period, the NKVD arrested 1.5 million people, purged from every stratum of Soviet society and every rank and file of the party, of which 681,692 people were killed as enemies of the state.
Neurotoxins, which primarily affect the nervous systems of animals, such as ion channel toxins. These are found in many venomous taxa, including mambas, black widow spiders, scorpions, box jellyfish, cone snails, centipedes and blue-ringed octopuses. Myotoxins, which damage muscles by binding to a receptor. These small, basic peptides are found in snake (such as rattlesnake) and lizard venoms. Cytotoxins, which kill individual cells and are found in the apitoxin of honey bees and the venom of black widow spiders. A subclass of cytotoxins is the necrotoxins, which cause necrosis (i.e., death) in the cells and tissues they encounter. The complex venoms of vipers and bees contain phospholipases; viper venoms often also contain trypsin-like serine proteases.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.